Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

552 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum: Functional impact and targetability of PI3KCA, GNAS, and PTEN mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation.
Choo F, Odintsov I, Nusser K, Nicholson K, Davis L, Corless CL, Stork L, Somwar R, Ladanyi M, Davis JL, Davare MA. Choo F, et al. Cold Spring Harb Mol Case Stud. 2022 Apr 28;8(3):a006216. doi: 10.1101/mcs.a006216. Print 2022 Apr. Cold Spring Harb Mol Case Stud. 2022. PMID: 35483883 Free PMC article. No abstract available.
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial.
Mowery YM, Ballman KV, Hong AM, Schuetze SM, Wagner AJ, Monga V, Heise RS, Attia S, Choy E, Burgess MA, Bae S, Pryor DI, Van Tine BA, Tinoco G, Chmielowski B, Freeman C, Gronchi A, Meyer CF, Dickson MA, Hartner L, Davis LE, Powers BC, Moding EJ, Weinhold KJ, van de Rijn M, Brigman BE, Riedel RF, Kirsch DG. Mowery YM, et al. Among authors: davis le. Lancet. 2024 Nov 23;404(10467):2053-2064. doi: 10.1016/S0140-6736(24)01812-9. Epub 2024 Nov 12. Lancet. 2024. PMID: 39547252 Clinical Trial.
Mycobacterium w - a promising immunotherapeutic intervention for diseases.
Stefan K, Gordon R, Rolig A, Honkala A, Tailor D, Davis LE, Modi RI, Joshipura M, Khamar B, Malhotra SV. Stefan K, et al. Among authors: davis le. Front Immunol. 2024 Oct 29;15:1450118. doi: 10.3389/fimmu.2024.1450118. eCollection 2024. Front Immunol. 2024. PMID: 39534596 Free PMC article. Review.
CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib.
Gelderblom H, Razak AA, Taylor MH, Bauer TM, Wilky B, Martin-Broto J, Gonzalez AF, Rutkowski P, Szostakowski B, Alcindor T, Saleh R, Genta S, Stacchiotti S, van de Sande M, Wagner AJ, Bernthal N, Davis LE, Vuky J, Tait C, Matin B, Narasimhan S, Sharma MG, Ruiz-Soto R, Sherman ML, Tap WD. Gelderblom H, et al. Among authors: davis le. Clin Cancer Res. 2024 Sep 13;30(18):3996-4004. doi: 10.1158/1078-0432.CCR-24-0103. Clin Cancer Res. 2024. PMID: 38995311 Free PMC article. Clinical Trial.
Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma.
Meyers PA, Federman N, Daw N, Anderson PM, Davis LE, Kim A, Macy ME, Pietrofeso A, Ratan R, Riedel RF, Trucco M, Breitmeyer JB, Toretsky JA, Ludwig JA. Meyers PA, et al. Among authors: davis le. J Clin Oncol. 2024 Nov;42(31):3725-3734. doi: 10.1200/JCO.24.00020. Epub 2024 Jul 2. J Clin Oncol. 2024. PMID: 38954782 Clinical Trial.
552 results